CommercialCoverageMedium impact
Antineoplaston Therapy (CPB 0240, reviewed 2026-04-13)
Aetna·Oncology, Palliative Care, Neurology·Medical Policy
Effective date
Apr 13, 2026
We identified it
Aug 12, 2026
Summary
Aetna reaffirms that antineoplaston therapy and all associated services (diagnostic monitoring, infusion supplies, catheter placement, and oral administration) remain experimental, investigational, and unproven. This is a policy review (not a new change) confirming non-coverage for antineoplaston treatments across all cancer indications and ALS. Billing teams must ensure claims for these services are denied and patients are informed of non-coverage status.
Action Required
By 2026-04-13: Billing team must verify that all antineoplaston therapy claims submitted to Aetna are flagged for automatic denial based on experimental/investigational status. Specifically: (1) Do NOT bill for antineoplaston infusions, oral antineoplaston therapy, or associated physician services; (2) Do NOT bill for ancillary diagnostics (labs, x-rays, MRI, CT scans) performed solely to monitor antineoplaston therapy; (3) Do NOT bill for infusion pumps, IV supplies, or Hickman catheter placement associated with antineoplaston treatment. Update billing system rules to route any antineoplaston-related claims to pre-billing review and deny with explanation: 'Service is experimental/investigational per Aetna CPB 0240.' Ensure patient financial counseling staff inform patients that Aetna will not cover these services and obtain documentation of non-coverage notification. Flag any appeals from patients or providers for supervisory review, as policy explicitly states no controlled trials support effectiveness.